Glenmark's cancer drug delivers high response in phase-1 trial, shows 74% response: Our Bureau, Mumbai Tuesday, June 3, 2025, 16:45 Hrs [IST] Ichnos Glenmark Innovation (IGI), a g ...

Ichnos Glenmark Innovation (IGI), a global, fully integrated clinical-stage biotechnology company focused on developing ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The early-stage trial results signal promise for ISB 2001, a first-in-class trispecific antibody being developed for patients ...

J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at ...

In the dose-escalation stage of the trial, 35 patients were treated, most of whom had received a median of six prior ...

During a live event, Samuel M. Rubinstein, MD, discussed the efficacy and safety outcomes from the KarMMa-3 trial.

ASCO 2025 will showcase cutting-edge advancements in precision medicine, artificial intelligence, and biomarker-driven therapies, revolutionizing cancer treatment and diagnostics.

Curriculum Associates has named Maggie Linneer of Tumbleweed School in Phoenix, Arizona to its 2025 class of Extraordinary Educators, an annual program that celebrates and connects teachers from ...

After more than 250 days in the NICU and nearly a year in temporary housing in Denver, Amy Humble and Corey Smith are doing what any parents would do: fighting to bring their daughter home, is what we ...